Remove Medical Remove Public Trading Remove Shares
article thumbnail

How Private Equity uses ‘Roll-up’ Strategies to Drive Investment Returns

OfficeHours

In this industry, owning 50 to 100 or more veterinary centers gives you procurement advantages in that you can buy much higher volumes of suppliers (syringes, medical equipment, etc.) For example, relevant platforms in this space include AmeriVet (owned by AEA and ADIA) and VetCor (owned by Oak Hill).

article thumbnail

Cooley’s M&A Insights for Q3 2022

Cooley M&A

The rise of founder-led, venture capital-backed companies in recent years has coincided with a surge of companies implementing dual-class share structures in connection with their initial public offerings. Notable public deals. Amazon to Acquire One Medical for $3.9 Sixth Street Invests in Blueprint Medicines.

M&A 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2019 Life Sciences M&A Year in Review

Cooley M&A

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 Year of the Life Sciences Mega-Deals. billion acquisition of The Medicines Company.

M&A 40
article thumbnail

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. Of the 20 largest public deals in the healthcare sector in 2021, 14 featured all?cash

M&A 40
article thumbnail

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

Newly public tech companies (particularly companies that went public via deSPAC transactions) may find themselves particularly in the crosshairs, given that they as a whole dramatically underperformed the broader market in 2022.

M&A 52